Ann Patterson
Family · Maquoketa, IANPI 1053544585
Payments from drug & device makers
Across 175 payments — averaging $15.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$553
- Amgen$352
- Novo Nordisk$197
- Astellas Pharma US Inc$186
- AbbVie$171
- Lilly USA, LLC$166
- plus $1K from 22 others
What the payments were for
- Food & beverage$2,65597%
- Education$803%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 35 | $553 |
| Amgen | 27 | $352 |
| Novo Nordisk | 13 | $197 |
| Astellas Pharma US Inc | 7 | $186 |
| AbbVie | 8 | $171 |
| Lilly USA, LLC | 11 | $166 |
| AstraZeneca | 9 | $141 |
| Boehringer Ingelheim | 8 | $128 |
| Mylan Specialty L.p. | 9 | $125 |
| Biohaven Pharmaceutical Holding Company Ltd. | 5 | $77 |
| Kowa Pharmaceuticals America, Inc. | 5 | $76 |
| Novartis | 5 | $75 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $57 |
| Sanofi Pasteur Inc. | 3 | $54 |
| Esperion Therapeutics, Inc. | 3 | $46 |
| Johnson & Johnson | 3 | $38 |
| Biohaven Pharmaceuticals, Inc. | 2 | $35 |
| Otsuka America Pharmaceutical, Inc. | 2 | $33 |
| Lexicon Pharmaceuticals, Inc. | 1 | $31 |
| Amarin Pharma, Inc. | 2 | $28 |
| E.r. Squibb & Sons, L.L.C. | 2 | $28 |
| GSK | 2 | $27 |
| Eisai Inc. | 2 | $26 |
| Biogen | 1 | $24 |
| Nestle Healthcare Nutrition Inc. | 1 | $16 |
| Harmony Biosciences LLC | 1 | $16 |
| Exact Sciences | 1 | $15 |
| Genentech USA, Inc. | 3 | $14 |
How this compares
$2,735 in reported general payments places this provider in the 90th percentile of 1,268 family providers in Iowa.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 22 | $39,257 |
| EliquisApixaban | 17 | $28,558 |
| FarxigaDapagliflozin Propanediol | 17 | $26,582 |
| MounjaroTirzepatide | 20 | $21,957 |
| TrulicityDulaglutide | 18 | $20,663 |
| TradjentaLinagliptin | 19 | $20,082 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 24 | $16,084 |
| OzempicSemaglutide | 11 | $10,711 |
| XareltoRivaroxaban | 12 | $9,957 |
| MyrbetriqMirabegron | 15 | $7,535 |
| PremarinEstrogens, Conjugated | 15 | $6,745 |
| Tresiba Flextouch U-100Insulin Degludec | 11 | $5,184 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 12 | $3,714 |
| Potassium Chloride | 134 | $3,232 |
| Omeprazole | 186 | $1,729 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Tradjenta | $128 | $59,33941 claims |
| Lilly USA, LLCMounjaro, Trulicity | $166 | $42,62038 claims |
| PfizerEliquis, Premarin | $553 | $35,30332 claims |
| AstraZenecaFarxiga | $141 | $26,58217 claims |
| GSKTrelegy Ellipta | $27 | $16,08424 claims |
| Novo NordiskOzempic | $197 | $10,71111 claims |
| Johnson & JohnsonXarelto | $38 | $9,95712 claims |
| Astellas Pharma US IncMyrbetriq | $186 | $7,53515 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,268 family providers in Iowa.
Other family in Maquoketa
- Stefanie GaticaAnkeny$354K
- Aubrey MolgaardAmes$238K
- Joan KittenFort Dodge$85K
- Megan FergusonPella$82K
- Rodney ClarkDes Moines$63K
- Jennifer CondonFort Dodge$31K
- Karen HunkeAmes$20K
- Tonia AckermanWest Des Moines$17K
- Chi-Ying SageWaterloo$14K
- Amanda GaldiNorth Liberty$14K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.